Second Genome Announces Inflammatory Bowel Disease Research Alliance with the APC Microbiome Institute at University College Cork
April 27, 2015, South San Francisco, CASecond Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, has entered into an alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC), Ireland, to advance the development of therapies that prevent and treat inflammatory bowel disease (IBD). Scientists from both groups will partner to explore the role of the microbiome in IBD by analyzing data from patients to identify new opportunities for therapeutic intervention.
Second Genome Advances Lead Microbiome Drug Development Program in Phase I Clinical Trial as a Treatment for Inflammatory Bowel Disease
January 12, 2015, South San Francisco, CASecond Genome, Inc., a pioneer in the development of novel medicines through innovative microbiome science, announced today that the company is advancing its lead drug candidate, SGM-1019, into a Phase I multiple-ascending dose clinical trial for the treatment of inflammatory bowel disease. SGM-1019 inhibits a target that Second Genome researchers discovered to be a key driver of inflammatory bowel disease when modulated by changes in the microbiome.